Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alina-Mihaela Gurau has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Skin Resilience and Biological Adaptability: Current Clinical Evidence on Micronutrients and Bioactive Compounds

    by Daniela Mihalache, Alina-Mihaela Gurau, Gabriela Patrichi, Gabriela Gurau, Catalin-Bogdan Satala

    Skin resilience and biological adaptability describe the capacity of cutaneous tissue to preserve structural integrity and functional stability under intrinsic aging and environmental stress. Rather than introducing a novel biological pathway, this framework integrates established domains, including redox homeostasis, extracellular matrix maintenance, inflammatory regulation, and barrier function, into a measurable construct. Micronutrients and bioactive compounds participate in these processes; however, the strength and clinical relevance of current evidence require critical evaluation. This structured narrative review appraises mechanistic and clinical studies published between 2000 and 2025 investigating nutritional modulation of measurable skin parameters. Electronic database searches (PubMed/MEDLINE, Scopus, Web of Science) were conducted using predefined terms related to skin aging, resilience-related endpoints, and micronutrient interventions. Controlled human trials were prioritized, and mechanistic findings were distinguished from clinical outcomes. Current clinical evidence most consistently supports a role for carotenoids and antioxidant vitamins in enhancing cutaneous redox stability and short-term photoprotection. Collagen-based formulations and selected polyphenols demonstrate modest improvements in elasticity, hydration, and wrinkle-related parameters, though many trials are limited by small sample sizes, short duration, and heterogeneous endpoints. Overall, micronutrients appear to function primarily as modulators of adaptive capacity rather than as primary drivers of structural rejuvenation. Larger, longer-term randomized trials employing standardized resilience-related endpoints are needed to clarify the magnitude and durability of clinically meaningful effects.

  • Open Access

    Gastric Cancer Biomarkers: From Cellular Identity to Precision Oncology

    by Catalin-Bogdan Satala, Alina-Mihaela Gurau, Gabriela Patrichi, Gabriela Gurau, Roxana-Cristina Mehedinti, Daniela Mihalache

    Gastric Cancer (GC) is characterized by remarkable biological heterogeneity, reflected by the continuous expansion of biomarkers with diagnostic, prognostic, predictive, and therapeutic relevance. However, most reviews organize these biomarkers according to signaling pathways or individual molecular alterations, often overlooking the interconnected biological processes and functional states that shape gastric carcinogenesis and tumor evolution. This review proposes a biology-oriented conceptual framework that interprets GC biomarkers through five fundamental biological questions capturing interconnected biological capabilities and tumor states: preservation of gastric lineage identity, acquisition of stem cell-like properties, epithelial–mesenchymal transition, immune evasion, and dependence on actionable oncogenic pathways. Within each biological domain, biomarkers were critically selected and comparatively evaluated according to their biological significance, pathological applicability, translational relevance, and clinical utility. Core biomarkers central to each biological process are discussed alongside complementary biomarkers that further refine biological interpretation and clinical stratification. Rather than presenting another comprehensive catalogue of molecular alterations, this review integrates current evidence into a coherent framework linking tumor biology with diagnostic pathology and precision oncology. By emphasizing biological capabilities rather than isolated molecular pathways, this approach provides a practical perspective for biomarker interpretation and establishes a conceptual foundation for future multimarker strategies in GC.

  • Open Access

    Recognizing the Benign Behind Worrisome Histology: A Case Report of Proliferative Fasciitis

    by Catalin-Bogdan Satala, Valerica Valentin Zaharia, Alina-Mihaela Gurau, Cristina-Mihaela Popescu, Robert Daniel Ciortan, Daniela Mihalache

    Background and Clinical Significance: Proliferative fasciitis (PF) is an infrequent benign fibroblastic/myofibroblastic proliferation that may closely resemble a soft tissue sarcoma, creating a diagnostic dilemma out of proportion to its biological behaviour. Because no single clinical, histological or immunohistochemical feature is diagnostic, accurate classification depends on the integration of complementary findings. We describe a challenging case of PF involving the lower leg and present a practical clinicopathological approach to its evaluation. Case Presentation: A 34-year-old man presented with a painless subcutaneous nodule on the lateral aspect of the left lower leg, discovered incidentally. Clinical examination suggested a benign superficial soft-tissue lesion, and because no features raised suspicion for malignancy, complete excision was performed without preoperative imaging. Gross examination revealed a 1.9 × 1.6 × 0.7 cm fascial-based lesion composed of spindle cells and scattered ganglion-like cells within a variably myxoid stroma. Focal nuclear pleomorphism, typical mitotic activity (2 mitoses/10 high-power fields), and limited extension into adjacent adipose tissue broadened the differential diagnosis. Immunohistochemistry demonstrated focal SMA positivity, weak focal desmin and S100 expression, absence of CD31 and CD34 staining, and a low Ki-67 proliferative index (approximately 2–3%). Negative surgical margins, together with integration of the clinical presentation, gross findings, histomorphology, and immunophenotype, supported the diagnosis of proliferative fasciitis. The patient remains free of local recurrence four months after surgery. Conclusions: PF should be considered in the differential diagnosis of superficial spindle-cell proliferations showing deceptively aggressive histological features. Careful clinicopathological correlation remains the cornerstone of diagnosis and helps distinguish this benign entity from its malignant mimics. The clinicopathological framework proposed in this report may assist pathologists in the systematic evaluation of similar diagnostically challenging lesions.

  • Open Access

    Decoding Cervical Neuroendocrine Carcinoma: A Practical Review of Diagnostic Pitfalls, Differential Diagnosis and Molecular Insights

    by Andreea Onofrei (Popa), Gabriela Gurau, Gabriela Patrichi, Alina-Mihaela Gurau, Roxana-Cristina Mehedinti, Catalin-Bogdan Satala

    Cervical neuroendocrine carcinoma (NECC) is a rare but highly aggressive cervical malignancy, accounting for approximately 1% of invasive cervical cancers. Diagnosis is challenging because NECC overlaps morphologically with other poorly differentiated cervical and metastatic tumors, may show crush artifact in small biopsies, and can display variable expression of conventional neuroendocrine markers. This narrative review provides a practical synthesis of the histopathological, immunohistochemical, molecular, and clinical features of NECC, with emphasis on diagnostic pitfalls and differential diagnosis. Recent English-language literature on cervical neuroendocrine carcinoma was reviewed and qualitatively integrated, focusing on morphology, immunohistochemistry, HPV association, molecular alterations, prognosis, and management-relevant diagnostic issues. Accurate diagnosis requires integration of morphology, epithelial differentiation, neuroendocrine marker expression, HPV-related context, and clinic-radiological correlation. Useful markers include broad-spectrum cytokeratins, synaptophysin, chromogranin A, CD56, INSM1, p16, and Ki-67, with additional markers selected according to the differential diagnosis. Diffuse block-type p16 expression and high-risk HPV detection support a cervical HPV-associated origin but are not specific for neuroendocrine differentiation. Molecular studies show frequent association with HPV18 and recurrent alterations involving PI3K/AKT, RAS/MAPK, and TP53-related pathways, although these findings remain insufficiently validated for routine prognostic or therapeutic stratification. NECC requires early recognition and a multimodal diagnostic approach because of its aggressive behavior and poor prognosis. A practical, stepwise integration of morphology, immunohistochemistry, molecular findings, and clinical–radiological data may improve diagnostic consistency and support multidisciplinary management.


  • Open Access

    From Primary Tumor to Peritoneal Niche: Microenvironmental Divergence in Gastric Cancer Peritoneal Metastasis

    by Catalin-Bogdan Satala, Alina-Mihaela Gurau, Daniela Mihalache, Gabriela Patrichi, Roxana-Cristina Mehedinti, Andy Radu Leibovici, Gabriela Gurău

    Gastric cancer peritoneal metastasis is not simply an extension of the primary tumor into the abdominal cavity. It represents a biologically distinct disease context shaped by interactions between disseminated tumor cells, peritoneal fluid, mesothelial surfaces, submesothelial stroma, extracellular matrix, immune populations, and malignant ascites. In this narrative review, we examine peritoneal metastasis as a transition between three related but physiologically different states: the primary gastric tumor, free-floating tumor cells or spheroids in the peritoneal fluid, and established mesothelial or submesothelial metastatic implants. We discuss how tumor cells acquire dissemination competence in the primary tumor, survive detachment and fluid-phase stress, adhere to remodeled mesothelium, recruit stromal and immune support, and adapt to ascites-mediated signaling. We also review how the peritoneal niche may contribute to biomarker discordance, immune exclusion, therapeutic resistance, and limitations of conventional response assessment. Where relevant, we distinguish evidence derived directly from gastric cancer peritoneal metastasis from preclinical data, extrapolation from other peritoneal malignancies, and hypothesis-generating interpretation. Finally, we summarize practical implications for tissue sampling, ascites and lavage analysis, biomarker interpretation, translational modeling, and peritoneal-directed therapeutic strategies. A clearer understanding of the biological divergence between the primary tumor, the fluid-phase compartment, and peritoneal implants may improve the study and clinical management of gastric cancer peritoneal metastasis.


  • Open Access

    FGFR2b in Gastric Cancer: Translating a Therapeutic Target into a Reliable Biomarker

    by Catalin-Bogdan Satala, Gabriela Gurău, Gabriela Patrichi, Alina-Mihaela Gurau, Roxana-Cristina Mehedinti, Andy Radu Leibovici, Daniela Mihalache

    Fibroblast growth factor receptor 2b (FGFR2b) has become an increasingly important therapeutic target in gastric and gastroesophageal junction cancer, particularly with the clinical development of FGFR2b-directed antibody therapy. However, its translation into routine treatment selection is not straightforward. FGFR2b is usually assessed as a protein biomarker by immunohistochemistry, and a positive result may reflect different biological situations depending on staining intensity, percentage of positive tumor cells, sample type and spatial distribution. In addition, FGFR2b protein expression, FGFR2 amplification, transcript-level activity and true pathway dependency are related but not interchangeable. This review examines FGFR2b-positive gastric cancer from the perspective of biomarker reliability rather than target presence alone. We discuss the biological basis of FGFR2b targeting, the reasons for variability in reported positivity rates, the implications of intratumoral and inter-lesion heterogeneity, the current clinical evidence for FGFR2b-directed and broader FGFR-targeted approaches, and the emerging challenges of safety, resistance and treatment sequencing. Particular attention is given to the gap between detecting FGFR2b and identifying tumors in which this target is sufficiently expressed, representative and biologically relevant to guide therapy. We also consider how FGFR2b should be interpreted alongside HER2, CLDN18.2, immune biomarkers and other receptor tyrosine kinase alterations. As FGFR2b-directed strategies move forward, their success will depend not only on drug efficacy, but also on standardized testing, careful reporting, and selective reassessment when disease biology changes. FGFR2b therefore offers a useful model for how protein biomarkers can be developed in gastric cancer: not as isolated positive-or-negative labels, but as clinically interpreted variables within a changing therapeutic landscape.


  • Open Access

    When Immunophenotype Is Not Identity: A Clinicopathological Review of Neuroendocrine Differentiation in Tumors of the Female Genital Tract

    by Catalin-Bogdan Satala, Alina-Mihaela Gurau, Gabriela Patrichi, Roxana-Cristina Mehedinti, Andy Radu Leibovici, Gabriela Gurau

    Neuroendocrine differentiation in tumors of the female genital tract is an uncommon but diagnostically consequential finding. Its interpretation is challenging because neuroendocrine marker expression does not necessarily define a neuroendocrine neoplasm. Focal or aberrant staining for synaptophysin, chromogranin A, CD56 or INSM1 may occur in otherwise conventional gynecologic carcinomas, whereas true poorly differentiated neuroendocrine carcinomas represent aggressive tumors with distinct prognostic and therapeutic implications. This narrative review examines neuroendocrine differentiation across the cervix, endometrium, ovary, vagina and vulva from an integrated clinicopathologic perspective. We emphasize that neuroendocrine differentiation should be approached as a diagnostic and biological spectrum, ranging from incidental immunophenotypic expression to carcinoma with neuroendocrine differentiation, mixed neuroendocrine/non-neuroendocrine tumors, well-differentiated neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas. Morphology remains the diagnostic anchor, while immunohistochemistry, molecular context and clinicoradiologic correlation refine classification and help exclude mimics or metastatic disease. Site-specific interpretation is essential: cervical neuroendocrine carcinoma is commonly HPV-associated and clinically aggressive; endometrial tumors require integration with p53, mismatch repair, POLE and SWI/SNF-related contexts; ovarian lesions demand distinction between primary well-differentiated neuroendocrine tumors, poorly differentiated carcinomas and metastases; and vaginal or vulvar tumors require careful exclusion of adjacent extension, cutaneous mimics and extragenital primaries. We propose a practical diagnostic framework that separates incidental marker expression from clinically meaningful neuroendocrine differentiation and links this distinction to reporting, prognosis and treatment. The central diagnostic question is not whether neuroendocrine markers are expressed but whether their expression defines a morphologically, biologically and clinically meaningful tumor category.


  • Open Access

    Fibroblast Growth Factor Receptor 2b (FGFR2b) in Gastric Cancer: The Challenge of Turning a Target into a Reliable Biomarker

    by Catalin-Bogdan Satala, Gabriela Gurău, Gabriela Patrichi, Alina-Mihaela Gurau, Roxana-Cristina Mehedinti, Daniela Mihalache

    Fibroblast growth factor receptor 2b (FGFR2b) has become an increasingly important therapeutic target in gastric and gastroesophageal junction cancer, particularly with the clinical development of FGFR2b-directed antibody therapy. However, its translation into routine treatment selection is not straightforward. FGFR2b is usually assessed as a protein biomarker by immunohistochemistry, and a positive result may reflect different biological situations depending on staining intensity, percentage of positive tumor cells, sample type and spatial distribution. In addition, FGFR2b protein expression, FGFR2 amplification, transcript-level activity and true pathway dependency are related but not interchangeable. This review examines FGFR2b-positive gastric cancer from the perspective of biomarker reliability rather than target presence alone. We discuss the biological basis of FGFR2b targeting, the reasons for variability in reported positivity rates, the implications of intratumoral and inter-lesion heterogeneity, the current clinical evidence for FGFR2b-directed and broader FGFR-targeted approaches, and the emerging challenges of safety, resistance and treatment sequencing. Particular attention is given to the gap between detecting FGFR2b and identifying tumors in which this target is sufficiently expressed, representative and biologically relevant to guide therapy. We also consider how FGFR2b should be interpreted alongside HER2, CLDN18.2, immune biomarkers and other receptor tyrosine kinase alterations. As FGFR2b-directed strategies move forward, their success will depend not only on drug efficacy, but also on standardized testing, careful reporting, and selective reassessment when disease biology changes. FGFR2b therefore offers a useful model for how protein biomarkers can be developed in gastric cancer: not as isolated positive-or-negative la-bels, but as clinically interpreted variables within a changing therapeutic landscape.

  • Open Access

    When Immunophenotype Is Not Identity: A Clinicopathological Review of Neuroendocrine Differentiation in Tumors of the Female Genital Tract

    by Catalin-Bogdan Satala, Alina-Mihaela Gurau, Gabriela Patrichi, Roxana-Cristina Mehedinti, Gabriela Gurau

    Neuroendocrine differentiation in tumors of the female genital tract is an uncommon but diagnostically consequential finding. Its interpretation is challenging because neuroendocrine marker expression does not necessarily define a neuroendocrine neoplasm. Focal or aberrant staining for synaptophysin, chromogranin A, CD56 or INSM1 may occur in otherwise conventional gynecologic carcinomas, whereas true poorly differentiated neuroendocrine carcinomas represent aggressive tumors with distinct prognostic and therapeutic implications. This narrative review examines neuroendocrine differentiation across the cervix, endometrium, ovary, vagina and vulva from an integrated clinicopathologic perspective. We emphasize that neuroendocrine differentiation should be approached as a diagnostic and biological spectrum, ranging from incidental immunophenotypic expression to carcinoma with neuroendocrine differentiation, mixed neuroendocrine/non-neuroendocrine tumors, well-differentiated neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas. Morphology remains the diagnostic anchor, while immunohistochemistry, molecular context and clinicoradiologic correlation refine classification and help exclude mimics or metastatic disease. Site-specific interpretation is essential: cervical neuroendocrine car-cinoma is commonly HPV-associated and clinically aggressive; endometrial tumors require integration with p53, mismatch repair, POLE and SWI/SNF-related contexts; ovarian lesions demand distinction between primary well-differentiated neuroendocrine tumors, poorly differentiated carcinomas and metastases; and vaginal or vulvar tumors require careful exclusion of adjacent extension, cutaneous mimics and extragenital primaries. We propose a practical diagnostic framework that separates incidental marker expression from clinically meaningful neuroendocrine differentiation and links this distinction to reporting, prognosis and treatment. The central diagnostic question is not whether neuroendocrine markers are expressed, but whether their expression defines a morphologically, biologically and clinically meaningful tumor category.


  • Open Access

    Tumor Budding in Gastric Carcinoma: Beyond Counting Cells at the Invasive Front—A Review of Current Evidence and Biological Perspectives

    by Catalin-Bogdan Satala, Gabriela Gurau, Alina-Mihaela Gurau, Gabriela Patrichi, Daniela Mihalache

    Tumor budding is increasingly recognized as a histopathologic feature associated with invasive behavior in gastrointestinal malignancies. While its prognostic value is well established in colorectal carcinoma, its significance in gastric adenocarcinoma remains less clearly defined because of marked morphologic heterogeneity, variable growth patterns, and the absence of gastric-specific assessment criteria. Multiple studies have associated high budding density with adverse clinicopathologic features, including lymph node metastasis, lymphovascular invasion, advanced tumor stage, and poorer survival, particularly in intestinal-type tumors. However, these associations are more difficult to interpret in diffuse-type and mixed carcinomas, where intrinsic discohesion and architectural variability complicate the distinction between true budding and baseline growth patterns. Beyond prognostic assessment, tumor budding has been linked to localized alterations in cell adhesion, cytoskeletal organization, tumor–stroma interaction, and partial epithelial–mesenchymal transition. Emerging evidence also suggests that its biological significance may differ across molecular subtypes of gastric cancer. This review examines the current evidence on the definition, morphologic spectrum, methodological limitations, and biologic context of tumor budding in gastric adenocarcinoma. We propose that, in gastric cancer, tumor budding is best interpreted not as a uniformly applicable scoring parameter, but as a context-dependent morphologic indicator of invasive tumor remodeling whose meaning varies according to tumor architecture, stromal interface, and molecular subtype.